Skip to content

Clinical efficacy of moxibustion at Zusanli(St36) in protection cardiovascular and cerebrovascular diseases on phlegm dampness type hypertension

Clinical efficacy of moxibustion in protection cardiovascular and cerebrovascular diseases on phlegm dampness type hypertension

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086582
Enrollment
Unknown
Registered
2024-07-05
Start date
2023-07-28
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

treatment group:Moxibustion at Zusanli
control group:Moxibustion at Xuanzhong

Sponsors

Shanghai East Hostipal
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Primary and secondary hypertension patients who meet the diagnostic criteria of Western medicine and meet the diagnostic criteria of phlegm dampness accumulation syndrome in traditional Chinese medicine; 2. Aged between 18 and 75 years old; 3. There is no medical contraindication of acupuncture and moxibustion; 4. Non secondary hypertension, no hyperthyroidism, no severe heart disease such as atrial fibrillation or moderate valvular heart disease, no unstable stage of angina or myocardial infarction, no acute stage of stroke, no malignant disease; 5. Interested in traditional Chinese medicine, willing to restore the body and prevent diseases from the perspective of constitution, and willing to jointly clarify the clinical efficacy and mechanism of acupuncture and moxibustion in traditional Chinese medicine; 6. Those who voluntarily join this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with severe mental disorders such as depression, anxiety, and schizophrenia, as well as those with severe illnesses that may require hospitalization or other intervention measures; 2. Pregnant or lactating patients; 3. Patients with heart, brain, liver, and kidney diseases; 4. Patients who are allergic to moxibustion and cannot tolerate moxibustion and cannot persist in treatment.

Design outcomes

Primary

MeasureTime frame
24-hour ambulatory blood pressure monitoring;

Secondary

MeasureTime frame
electrocardiogram and heart rate variability;TC, TG, HDL, LDL;Fasting blood glucose;glycosylated hemoglobin;Fasting insulin;liver function;renal function;blood pressure;heart rate;BMI;waist to hip ratio;TCM phlegm-dampness constitution integral;Cognitive Rating;

Countries

China

Contacts

Public ContactCheng Ling

Shanghai East Hostipal

Chlrosy.east@sina.com+86 137 0185 4848

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026